Funding awarded
- Theranostic Trop-2-directed pretargeted radioimmunotherapy for metastatic prostate cancer with curative intent awarded by United States Department of Defense Key Personnel 2025 - 2028
- DOTA-based pre-targeting of alpha emitters awarded by National Cancer Institute Key Personnel 2022 - 2024